Anika Therapeutics (ANIK) (fka )

[BioSpecialist]

4 FDA approvals this Q(Mcap 96 M) Hot Pick 2011

With a market value of $96 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena .ANIK has been profitable for each of the past seven years.

2011 Price Target: $25.00+ .Get in now before the stock gets Discovered .Buy with both hands now and you will make a lot of money with the upcoming FDA approvals .Anika is a once in a lifetime opportunity .GLTA


Anika Therapeutics (ANIK)

Market-Cap: 96 Mil
Cash: 26 Mil
Price: 7.20

Shares Out: 13.5


UPCOMING MILESTONES :

Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential

Hyaloglide 510(K) expected FDA approval 1Q 2011

Hyalonect 510(K) expected FDA approval 1Q 2011

Hyalofast 510(K) expected FDA approval 1Q 2011



Big Pipeline
http://www.anikatherapeutics.com/innovation/pipeline/index.html


Insider Ownership
http://www.dailyfinance.com/company/anika-therapeutics-inc/anik/nas/institutional-ownership


http://www.anikatherapeutics.com/innovation/spotlight/index.html

FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:

* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;

* Hyalonect®, a knitted mesh used as a bone graft wrap; and

* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.

We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.

Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.